PRRT Plus Somatostatin Analogs Achieved Complete Pathological Response in Unresectable Liver Metastases from Pancreatic NET | Research

The takeaway

Combined peptide receptor radionuclide therapy (PRRT) and somatostatin analogs converted initially unresectable liver metastases from a pancreatic neuroendocrine tumor to a pathological complete response.

Pathological complete response
Initially unresectable liver metastases showed no living tumor cells after PRRT and somatostatin analog combination therapy

What the researchers found

PRRT combined with somatostatin analogs achieved pathological complete response of initially unresectable multiple liver metastases from a pancreatic neuroendocrine tumor, enabling curative surgical resection.

Why it matters

Complete pathological responses to PRRT are rarely documented. This case demonstrates that peptide-targeted radionuclide therapy can potentially convert unresectable metastatic disease into a surgically curable condition — representing the best possible outcome of targeted peptide therapy.

The numbers in context

1 patient; multiple initially unresectable liver metastases; complete pathological response after PRRT + somatostatin analogs.

How the study worked

Single case report of a 52-year-old male with pancreatic NET and initially unresectable liver metastases treated with PRRT and SSAs, followed by conversion surgery with pathological assessment.

Who was studied

Patient with pancreatic NET and initially unresectable multiple liver metastases

What this study cannot tell us

Single case report — cannot generalize outcomes. Pathological complete responses to PRRT are very rare. Patient selection factors (tumor grade, receptor expression, metastatic burden) heavily influence outcomes. No long-term recurrence data provided.

How to read the evidence

Preliminary evidence — single case report of an exceptional outcome. Hypothesis-generating but cannot establish expected response rates.

When this study was published

Published in 2024. Reflects current PRRT and somatostatin analog combination protocols.

The bigger picture

This case represents a best-case scenario for peptide receptor radionuclide therapy — moving from palliative intent to curative surgery. As PRRT protocols improve and are combined with other therapies, more patients with metastatic NETs may achieve similar conversion to operability.

Questions still open

What percentage of patients with unresectable NET liver metastases can achieve conversion to surgery after PRRT?
Does pathological complete response after PRRT predict long-term cure or is recurrence still likely?
Should all patients with unresectable somatostatin receptor-positive NET metastases receive PRRT as first-line therapy?

Common questions

Can radiation peptide therapy cure liver metastases from neuroendocrine tumors?

In this remarkable case, yes — PRRT (which delivers radiation via tumor-targeting peptides) combined with somatostatin drugs completely eliminated living tumor cells in liver metastases that were initially too extensive to remove surgically. However, this complete response is rare, and most patients achieve tumor control rather than complete elimination.

What is conversion surgery after PRRT?

Sometimes tumors that are initially too large or widespread for surgery can shrink enough with treatment to become operable. In this case, PRRT shrank the liver metastases enough that surgeons could remove them — and found no living tumor cells remaining. This 'conversion' from inoperable to operable is one of the most important potential benefits of PRRT.

Read the original research

Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report.

Surgical case reports, 10(1), 40

View on PubMed ↗Publisher’s paper ↗

Citation

Umino, Ryosuke; Nara, Satoshi; Kobayashi, Noritoshi; Mizui, Takahiro; Takamoto, Takeshi; Ban, Daisuke; Esaki, Minoru; Hiraoka, Nobuyoshi; Shimada, Kazuaki. (2024). Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report.. Surgical case reports, 10(1), 40. https://doi.org/10.1186/s40792-024-01839-4